The Joint Corp. | NASDAQ: JYNT | thejoint.com

# Preliminary Q2 2023 Investor Presentation

As of June 30, 2023 | Reported on September 13, 2023





#### **Safe Harbor Statements**

Certain statements contained in this presentation are "forward-looking statements" about future events and expectations. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations of future results we express or imply in any forward-looking statements, and you should not place undue reliance on such statements. Factors that could contribute to these differences include, but are not limited to, our preliminary results differing from final results, possible negative effects of the restatement of our financial statements for 2021 and 2022 on our financial position, results of operations and cash flows, increases in our borrowing costs under our credit facility, given that borrowings under the credit facility bear interest at rates tied to certain rising benchmark interest rates; state laws limiting the use our business model, including prohibitions on advance payment for chiropractic services, which recently caused us to elect not to offer franchises in South Dakota and Wyoming; increased costs to comply with a new SEC reporting rule enhancing and standardizing disclosures regarding cybersecurity incidents and cybersecurity risk management, inability to identify and recruit enough qualified chiropractors and other personnel to staff our clinics, due in part to the nationwide labor shortage, an increase in operating expenses due to measures we may need to take to address such shortage, inflation, exacerbated by COVID-19 and the current war in Ukraine, which has increased our costs and which could otherwise negatively impact our business, the potential for further disruption to our operations and the unpredictable impact on our business of the COVID-19 outbreak and outbreaks of other contagious diseases, our failure to develop or acquire company-owned or managed clinics as rapidly as we intend, our failure to profitably operate company-owned or managed clinics, short-selling strategies and negative opinions posted on the internet which could drive down the market price of our common stock and result in class action lawsuits, our failure to remediate any material weaknesses in our internal control over financial reporting, which could negatively impact our ability to accurately report our financial results, prevent fraud, or maintain investor confidence, and other factors described in our filings with the SEC, including in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 10, 2023 and subsequently-filed current and quarterly reports. Words such as, "anticipates," "believes," "continues," "estimates," "expects," "goal," "objectives," "intends," "may," "opportunity," "plans," "potential," "near-term," "long-term," "projections," "assumptions." "projects." "guidance." "forecasts." "outlook." "target." "trends." "should." "could." "would." "will." and similar expressions are intended to identify such forward-looking statements. We gualify any forward-looking statements entirely by these cautionary factors. We assume no obligation to update or revise any forward-looking statements for any reason or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

#### **Business Structure**


The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Washington, West Virginia and Wyoming, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices.







Quality, convenient, affordable chiropractic care in a retail setting





Serving patients seeking pain relief and ongoing health and wellness





A proven membership-based, walk-in, no-insurance model in an open bay setting

## **Strong Operational KPIs**

12.2M

adjustments in 2022

Up from 10.9M in 2021

1.6M

unique patients treated in 2022

Up from 1.4M in 2021

845K

new patients in 2022

Compared to 807K in 2021

35%

of new patients were new to chiropractic<sup>1</sup>

> ~296K patients in 2022 had never been to a chiropractor before

84%


system-wide gross sales memberships in 2022

Compared to 85% in 2021



#### **Upside for Future Growth**

\$19.5B growing chiropractic market<sup>1</sup>



know what the word "chiropractic" means 30%

understand chiropractic but are scared


16%

saw a chiropractor in the last 12 months



#### **Substantial Opportunity for Market Share Growth**

- \$134B annual spending on back pain <sup>1</sup>
- \$19.5B annual spending on chiropractic care<sup>2</sup>
- ~4% of chiropractic offered at chains<sup>3</sup> vs. ~12% for dentistry chains (DSOs)4
- 80% of Americans experience back pain at least once in their lifetime<sup>5</sup>






#### Only 4.9% of Franchise Concepts Have 500+ Units

Percentage of Franchise Brands by # of Units

Only 94 brands have over 1000 units.






#### JYNT Sales ~2.3x Independent Collections per Clinic











\*2021 Chiropractic Economics Compensation Survey



# **Top Franchise Recognition... Again**














# **Growing Market Opportunity**



#### Mid-term Market ~1950 Potential Clinics

#### The Joint Patient Base

With usable addresses

- All 50 States, DC and Puerto Rico
- All Canadian Provinces and Territories
- 66 Countries on 6 Continents

# Similar Points of Distribution

- Analyze demographics and psychographics
- Model attributes
- Roll across country


# The Joint: First Mover Advantage

Companies	<b>Clinics</b> at 6/30/23	<b>Clinics</b> at 12/31/17	Change in Clinics	States	Franchise	Owned/ Managed	Insurance	Private Pay
The Joint Corp.	890	399	491	41	✓	✓		✓
Airrosti	156	177	(21)	5		✓	✓	✓
HealthSource Chiropractic	137	295	(158)	33	✓		✓	✓
100% Chiropractic	113	*	0	22	✓		✓	✓
ChiroOne	101	41	60	7		✓	✓	
AlignLife Chiropractic	37	23	14	13	✓	✓	✓	✓
Chiropractic Company	23	*	0	1		✓	✓	✓
Aligned Modern Health	18	*	0	1		✓	✓	✓
NuSpine	30	3	27	10	✓			✓
Chiropractic Partners	12	*	0	1		✓	✓	✓
20 Dollar Chiropractic	10	*	0	1	✓			✓
The BackSpace	5	*	0	3		✓		✓
Chiro Now!	10	*	0	1	✓	✓		✓
ChiroWay	11	8	3	3	✓			~
Express Chiropractic	6	0	6	1	✓			~
SnapCrack Chiropractic	5	*	0	1	✓			~
Independent Offices	39,534	38,801	733	50				

	Q2 2023	Q2 2022
Franchise Licenses Sold	21	24
Total New Franchised Clinics Opened	23	31
Greenfield Clinics Opened	3	3
Franchised Clinics Acquired	3	4
Clinics in Development	214	270
THIOL <sup>THE</sup>		

chiropractic

## 26 New Clinics in Q2 2023



<sup>&</sup>lt;sup>1</sup> In Q2 2023, The Joint closed four franchised clinics and two corporate-owned or managed clinics. In Q2 2022, The Joint closed one franchised clinics. The closure rate remains one of the lowest in the franchise community at less than 1 percent.

890

Locations

**756** 

Franchised Clinics


134

Corporate Clinics

As of 6/30/2023




# **Growing National Footprint**




## **Pipeline for Growth**

#### **Franchise Licenses Sold Annually**




67% sold by Regional Developers in 2022

#### Clinics in Active Development<sup>1</sup>



Gross Cumulative Franchise Licenses Sold<sup>1</sup>



69% of clinics supported by 18 RDs as of Dec. 31, 2022

RD territories cover 55% of Metropolitan Statistical Areas (MSAs) as of Dec. 31, 2022



#### ~\$300k Investment


- ~\$200K initial build-out
- Chart includes:
  - 2% of gross sales for the National Marketing Fund
  - Local marketing expenses, wages, rent and G&A expenses
- Chart excludes:
  - \$599 per month tech fee
  - 7% royalty on gross sales
  - \$39.9K per license, prior to year 1 sales
- Assumes breakeven monthly gross sales¹ of ~\$30k - \$33k



#### **Strong Clinic Economics**

Estimated cash-on-cash return reduced from 5+ years to ~4 years

System-wide Sales & Potential Company-owned/Managed Contribution<sup>1</sup> (5 yr. avg., \$ in 000s)



<sup>&</sup>lt;sup>1</sup>Breakeven varies on a clinic-by-clinic basis based on actual gross sales and operating expenses. This represents operating income excluding income taxes and depreciation.

#### **Building upon Foundation for Growth**

13%

Increase in system-wide sales Q2 2023 over Q2 2022<sup>1</sup> 5%

Increase in comp sales<sup>1</sup> for all clinics >13 months in operation Q2 2023 over Q2 2022<sup>2</sup>

(1)%

Decrease in comp sales<sup>1</sup> for all clinics >48 months in operation Q2 2023 over Q2 2022<sup>2</sup>





<sup>1</sup>System-wide sales include revenues at all clinics, whether operated or managed by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company's financial performance, because these revenues are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. | <sup>2</sup> Comparable sales include only the sales from clinics that have been open at least 13 or 48 full months and exclude any clinics that have permanently closed.

## **Amended Preliminary 2023 Financial Guidance**

\$ in M	2022 Actual	2023 Low Guidance	2023 High Guidance
Revenues	\$101.9	\$115.0	\$118.0
Adjusted EBITDA <sup>1</sup>	\$11.5	\$11.0	\$12.5
New Franchised Clinic Openings	121	100	120
New Greenfield Clinics <sup>2</sup>	16	8	12



<sup>&</sup>lt;sup>1</sup> Reconciliation of Adjusted EBITDA to GAAP earnings is included in the appendix. | <sup>2</sup> Historically, company-owned or managed clinic openings included a combination of both greenfields and acquisitions. The company will continue to acquire previously franchised clinics. However, as these transactions are opportunistic, management will no longer include the acquired clinic estimate in guidance. To provide greater clarity, the 2023 company-owned or managed guidance includes greenfield clinic openings only.

People will continue to seek more noninvasive, holistic ways to manage their pain.

We'll be there to treat them.


# THE JOHT chiropractic

#### **Leading Market Growth**

The Joint Corp. 12-yr. CAGR 62%1 vs. Industry 5-yr. CAGR 5.1%2

#### **System-wide Sales**

(\$ in M)



<sup>&</sup>lt;sup>1</sup> For the period ended Dec. 31, 2022

<sup>&</sup>lt;sup>2</sup> March 2023 Kentley Insights Chiropractic Care Market Research Report

## **Driving Long-term Shareholder Value**

The most powerful brand-building tool is **our storefronts**.





# Appendix



# **Preliminary Q2 2023 Financial Results**

\$ in M <sup>1</sup>	<b>Q2 2023</b> (unaudited)	<b>Q2 2022</b> (as restated, unaudited)	Differ	ences	
Revenue • Corporate clinics • Franchise operations	\$29.3 17.8 11.5	\$24.9 14.5 10.4	\$4.4 3.3 1.1	18% 23% 11%	
Cost of revenue	2.6	2.3	0.3	15%	
Sales and marketing	4.7	3.8	0.9	23%	
Depreciation and amortization	2.3	1.5	0.8	59%	
G&A	19.9	18.6	1.3	7%	
Operating (loss)	(0.4)	(1.3)	1.0	NA	
Other (expense)	(O.1)	(O.O)	(O.1)	NA	
Loss) before income tax expense	(O.5)	(1.3)	(0.9)	NA	
Adj. EBITDA <sup>2</sup>	3.2	2.6	0.6	23%	



 $<sup>^{\</sup>mbox{\scriptsize 1}}\mbox{\scriptsize Due}$  to rounding, numbers may not add up precisely to the totals.

<sup>&</sup>lt;sup>2</sup> Reconciliation of Adjusted EBITDA to GAAP earnings is included in the Appendix.

## **Preliminary YTD June 30, 2023 Financial Results**

\$ in M <sup>1</sup>	<b>H1 2023</b> (unaudited)	<b>H1 2022</b> (as restated, unaudited)	Differ	ences
Revenue • Corporate clinics • Franchise operations	\$57.6 34.9 22.7	\$47.1 27.1 20.0	\$10.5 7.8 2.7	22% 29% 12%
Cost of revenue	5.1	4.4	0.7	16%
Sales and marketing	8.9	7.1	1.7	24%
Depreciation and amortization	4.5	2.8	1.7	62%
G&A	39.9	34.1	5.8	17%
Operating (loss)	(1.0)	(1.4)	0.4	NA
Other income <sup>3</sup>	3.7	0.0	3.7	NA
Income (loss) before income tax expense	2.7	(1.4)	4.1	NA
Adj. EBITDA <sup>2</sup>	5.3	4.4	0.9	19%



<sup>&</sup>lt;sup>1</sup>Due to rounding, numbers may not add up precisely to the totals.

<sup>&</sup>lt;sup>2</sup>Other income in Q1 2023 includes net employee retention credits of \$3.9 million.

<sup>&</sup>lt;sup>3</sup> Reconciliation of Adjusted EBITDA to GAAP earnings is included in the Appendix.

#### **Executive Team**

















							The Access of th
Peter D. Holt	Jake Singleton	Lori Abou Habib	Krischelle Tennessen	Charles Nelles	Jorge Armenteros	Eric Simon	Dr. Steve Knauf
President & CEO  Tasti D-Lite Planet Smoothie Mail Boxes Etc. The UPS Store I Can't Believe It's Yogurt	CFO  • EY  • American Institute of CPAs	CMO  SONIC® Americ a's Drive-In®, part of the Inspire Brands CKE Restaurants, Inc. Eateries, Inc.	CHRO  • Five Below • Marvin Windows & Doors • Kum & Go • Walmart • Target	CTO  • American Express Global Business Travel • Western Union • The Children's Hospital of Denver • PacifiCare Health Systems	SVP, Operations  Togo's Dunkin' Donuts Baskin Robbins Pollo Campero	VP, Franchise Sales Aamco Mail Boxes Etc. UPS Store Extreme Pita	VP of Chiropractic & Compliance  • Arizona Board of Chiropractic Examiners  • Northwestern Health Sciences University  • International Chiropractors Assn.  • American Chiropractic Assn.  • Health Care Compliance Assn.
MA, Univ. of London BA, Univ. of Washington	MA, Univ. of Arizona BS, Univ. of Arizona	MBA, Webster International Univ. BA, Univ. of Central Oklahoma	MAOM, Univ. of Phoenix BA, Univ. of Minnesota - Winona	BA, Univ. of Phoenix, Certified PMP		BA, Univ. of Rhode Island	DC, Northwestern Health Sciences Univ. BS, Northwestern Health Sciences Univ.



#### **Board of Directors**













Matthew E. Rubel	Ronald V. DaVella, CPA	Suzanne M. Decker	Peter D. Holt	Abe Hong	Glenn J. Krevlin
Lead Director, 2017	Director, 2014	Director, 2017	Director, 2016	Director, 2018	Director, 2019
<ul> <li>Executive Chair KidKraft, Inc.</li> <li>Chair, Holley Inc. &amp; Mid Ocean Ptrs. PE Consumer Group</li> <li>Former Dir. Hudson's Bay Co., HSNi &amp; Treehouse Foods</li> <li>Former: Roark Capital, TPG Capital, TPG Growth, Varsity Brands, Collective Brands, Cole Haan, J Crew, Popular Club Plan and more</li> <li>Pres. Appointee, House Advisory Council on Trade Policy Negotiation</li> </ul>	<ul> <li>Financial Advisor: Manufacturing Succession Holding, and Universal Health</li> <li>Vice Chair of the Strategic Advisory Board of Aura Ventures</li> <li>Dir. Alkaline Water Co., Universal Health Group, Delta Dental of Arizona, and NorthStar Security</li> <li>Former: Deloitte &amp; Touche Mobile Home Parks NanoFlex Power Corp. and Amazing Lash Studio CFO &amp; franchisee</li> </ul>	<ul> <li>Former Exe. Project Sponsor and Chief HR Officer, Aspen Dental Mgmt</li> <li>HR &amp; Talent Acquisition Advisor, Bond Veterinary</li> <li>Former Dir. Refresh Mental Health Davis Vision Companies</li> </ul>	<ul> <li>Pres. &amp; CEO, The Joint Corp.</li> <li>Former Mgmt.: <ul> <li>Tasti D-Lite</li> <li>Great Hills Partners</li> <li>Mail Boxes, Etc. (now The UPS Store)</li> <li>Director Intl.! Franchise Assn. (IFA)</li> <li>Chair, International Affairs Network (IAN)</li> </ul> </li> </ul>	<ul> <li>EVP &amp; CTO, Learning Care Group</li> <li>Former Mgmt.: <ul> <li>Discount Tire Company</li> <li>Red Rock Resorts</li> <li>Starbucks Corp.</li> <li>Technologent</li> </ul> </li> </ul>	<ul> <li>Founder, Managing Partner, &amp; PM Glenhill Capital Advisors</li> <li>Dir. Ember Technologies</li> <li>Former Mgmt. or Dir.</li> <li>Centric Brands</li> <li>Design within Reach</li> <li>Restoration Hardware</li> <li>Cumberland Associates</li> <li>The Goldman Sachs Group</li> </ul>

BS, Ohio University MBA, University of Miami

BS, Queens College MBA, Pace University

BS, Russell Sage College

BA, Univ. of Washington MA, University of London BE, U.S. Military Academy at West Point BA, Wesleyan University MBA, New York University


## **Revolutionizing Access to Chiropractic Care**

Features	Industry Problems	The Joint's Solutions
Affordability (per appointment)	\$64 Average <sup>1</sup>	\$36 Average
Convenient Locations	Medical Centers/Offices	Retail Locations
Multiple Locations	Limited Locations	890 Clinics
Walk-in / No Appointment	Appointments Required	No Appointments
Insurance / Caps / Co-pays	Yes	Private Pay
Inviting, Consumer-centric Design	Clinical	Approachable, Consumer Friendly
Service Hours	Limited / Inconsistent	Open 6-7 Days + Nights & Weekends <sup>2</sup>
Average Patient Visits per Clinic	115 per week <sup>1</sup>	321 per week <sup>3</sup>



# **Patient Demographics**

	The Joint
Median Age	37.6 Years
Generation Mix	
Gen Z	19%
Millennial	45%
Gen X	25%
Baby Boomer	11%
Gender	
Female	49%





## **Transformative Opportunity for Chiropractors**

	Industry	The Joint	
Annual Salary	Median \$81,240 <sup>1</sup>	Starting \$85,000 <sup>2</sup>	Our r through routing quality iropractic C
Accessibility	<ul><li>Appointments required</li><li>Medical centers &amp; offices</li><li>Traditional office hours</li></ul>	<ul> <li>No appointments</li> <li>Clustered, high-visibility retail locations</li> <li>Open evenings + weekends<sup>3</sup></li> </ul>	quality iropractic C
Practice & Insurance	<ul> <li>Challenges of managing a business without support</li> <li>Difficulty attracting new patients</li> <li>Insurance hassles</li> <li>Slow payment cycle</li> </ul>	<ul> <li>Proprietary CRM and POS software</li> <li>Ongoing training and coaching</li> <li>Ability to perfect technique</li> <li>Less administration</li> <li>Higher patient focus</li> <li>Better cash flow</li> </ul>	THE CO Chiropra



<sup>&</sup>lt;sup>2</sup> Based on Joint Corp. company-owned or managed actual salaries | <sup>3</sup> Hours vary by clinic

#### **Performance Metrics and Non-GAAP Measures**

This presentation includes commonly discussed performance metrics. System-wide sales include sales at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company's financial performance, because these sales are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. Comp sales include the sales from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.

This presentation includes non-GAAP financial measures. EBITDA and Adjusted EBITDA are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the Company's underlying operating performance and operating trends than GAAP measures alone. Reconciliations of net loss to EBITDA and Adjusted EBITDA are presented where applicable. The Company defines EBITDA as net income/(loss) before net interest, tax expense, depreciation, and amortization expenses. The Company defines Adjusted EBITDA as EBITDA before acquisition-related expenses, bargain purchase net gain, gain/(loss) on disposition or impairment, stock-based compensation expenses and employee retention credits.

EBITDA and Adjusted EBITDA do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States, or GAAP. While EBITDA and Adjusted EBITDA are frequently used as measures of financial performance and the ability to meet debt service requirements, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA and Adjusted EBITDA should be reviewed in conjunction with the Company's financial statements filed with the SEC.



#### Prel. Q2 2023 Segment Results as of June 30, 2023

\$ in 000s




Total Revenues
Total Operating Costs
Operating Income (Loss)
Other Income Expense, net
Income (Loss) Before Income Tax Expense
Total Income Taxes
Net Income (Loss)
Net Interest Expense
Income Taxes
<b>Total Depreciation and Amortization Expense</b>
EBITDA
Stock Based Compensation Exp
Loss on Disposition/Impairment
Acquisition Expenses
Other Expense, net
Adjusted EBITDA

 Corporate Clinics	Franchise Operations	Unallocated Corporate	The Joint Consolidated
\$ 17,803	\$ 11,504	\$ -	\$ 29,307
(17,781)	(7,272)	(4,629)	(29,682)
22	4,232	(4,629)	(375)
-	-	(107)	(107)
22	4,232	(4,735)	(481)
-	-	(291)	(291)
22	4,232	(4,444)	(190)
-	-	15	15
-	-	(291)	(291)
2,033	208	89	2,329
2,054	4,440	(4,631)	1,863
-	-	417	417
144	-	-	144
7	709	-	716
-	-	92	92
\$ 2,206	\$ 5,149	\$ (4,123)	\$ 3,232



#### Prel. YTD Segment Results as of June 30, 2023

\$ in 000s



Total Revenues
Total Operating Costs
Operating Income (Loss)
Other Income Expense, net
Income (Loss) Before Income Tax Expense
Total Income Taxes
Net Income (Loss)
Net Interest Expense
Income Taxes
<b>Total Depreciation and Amortization Expense</b>
EBITDA
Stock Based Compensation Exp
Loss on Disposition/Impairment
Acquisition Expenses
Other Expense, net
Adjusted EBITDA

Corporate	Franchise	Unallocated	The Joint
Clinics	Operations	Corporate	Consolidated
\$ 34,931	\$ 22,677	\$ -	\$ 57,608
(35,331)	(13,903)	(9,402)	(58,636)
(400)	8,774	(9,402)	(1,028)
-	-	3,715	3,715
(400)	8,774	(5,687)	2,687
-	-	551	551
(400)	8,774	(6,238)	2,136
-	-	65	65
-	-	551	551
3,960	407	178	4,544
3,559	9,181	(5,444)	7,296
-	-	683	683
210	-	-	210
46	812	-	858
-	-	(3,779)	(3,779)
\$ 3,816	\$ 9,992	\$ (8,540)	\$ 5,268



#### **Preliminary GAAP – Non-GAAP Reconciliation**

\$ in 000s

	RESTATED	R	ESTATED	RESTATED	RESTATED			RESTAT	ED	RES	STATED	RES	TATED	RES	TATED			RESTATED				
	Quarter		Quarter	Quarter	Quarter			Quart	er	Q	uarter	Q	uarter	Q	uarter			Quarter		Quarter		
	Ending		Ending	Ending	Ending			Ending Ending		_	Ending		Ending			Ending		Ending				
	03/31/20	21	06/30/2021	09/30/2021	12/31/20	21		03/31/	2022	06	/30/2022	09	/30/2022	12	2/31/2022			03/	31/2023	6/3	0/2023	
	Q1-21		Q2-21	Q3-21	Q4-21		FY21	Q1-2	2	(	Q2-22	Ç	3-22	(	24-22		FY22		Q1-23	Q2-23		
Total Revenue	17,33	0	20,004	20,782	21,89	5	80,011	22,	237		24,887		26,450		27,678		101,252		28,301		29,307	
Total Cost of Revenue	1,54	7	1,824	2,090	2,20	3	7,665	2	2,111		2,257		2,337		2,466		9,171		2,475	75 2,596		
Gross Profit	\$ 15,78	3 \$	18,180	\$ 18,691	\$ 19,69	1 \$	72,346	\$ 20,	126	\$	22,630	\$	24,113	\$	25,212	\$	92,081	\$	25,826	\$	26,712	
Sales & Marketing	2,48	9	3,133	2,882	2,92	27	11,424	3,	287		3,840		3,539		3,296		13,963		4,160		4,708	
Depreciation/Amortization Expen	62	8	901	1,120	1,27	2	3,922	1,	337		1,462		1,780		2,068		6,647		2,215		2,329	
Other Operating Expenses	11,51	5	11,580	12,819	14,96	0	50,874	15,5	540		18,659		18,061		18,383		70,644		20,104		20,049	
Total Other Income (Expense)	(2	2)	(16)	(16)	(1	6)	(70)		(16)		(19)		(25)		(72)		(133)		3,821		(107)	
Total Income Taxes	(69	4)	(628)	(576)	38	9	(1,509)		(38)		(475)		(41)		622		68		842		(291)	
Net Income (Loss)	\$ 1,82	3	\$ 3,178	\$ 2,431	\$ 134	4 \$	7,565	\$	(17)	\$	(875)	\$	748	\$	771	\$	627	\$	2,326	\$	(190)	
Net Interest Expense	2	2	16	16	1	6	70		16		19		25		72		133		50		15	
Income Taxes	(69	4)	(628)	(576)	38	9	(1,509)		(38)		(475)		(41)		622		68		842		(291)	
Depreciation and Amortization Ex	62	8	901	1,120	1,27	2	3,922	1,	337		1,462		1,780		2,068		6,647		2,215		2,329	
EBITDA	\$ 1,77	9 \$	3,467	\$ 2,991	\$ 1,81	1 \$	10,048	\$ 1,2	298	\$	131	\$	2,512	\$	3,533	\$	7,475	\$	5,433	\$	1,863	
Stock Based Compensation	24	6	284	297	22	9	1,056		324		340		306		304		1,274		266		417	
Loss on Disposition/Impairment	6	5	(44)	(4)	10	0	27		7		89		264		50		410		65		144	
Acquisition Expenses	1,35	9	39	3	20	0	1,422		155		2,074		47		81		2,356		142		716	
Other (Income)/Expense, net	-		-	-	-		-		-		-		-		-		-		(3,871)		92	
Adjusted EBITDA	\$ 3,44	9 \$	3,746	\$ 3,287	\$ 2,070	9 \$	12,552	\$ 1,7	783	\$	2,635	\$	3,129	\$	3,968	\$	11,515	\$	2,035	\$	3,232	



#### **Contact Information**



Peter D. Holt, President & CEO peter.holt@thejoint.com

The Joint Corp. | 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245-5960



Jake Singleton, CFO jake.singleton@thejoint.com

The Joint Corp. | 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245-5960



Kirsten Chapman, LHA Investor Relations <a href="mailto:thejoint@lhai.com">thejoint@lhai.com</a>

LHA Investor Relations | 50 California Street, Suite 1500 | San Francisco, CA 94111 | (415) 433-3777



https://www.facebook.com/thejointchiro@thejointchiro



https://twitter.com/thejointchiro@thejointchiro



https://www.youtube.com/thejointcorp@thejointcorp

